Abstract
Background Value of radiomics features from the adrenal gland and periadrenal fat CT images for predicting disease progression in patients with COVID-19 has not been studied.
Methods A total of 1,245 patients (685 moderate and 560 severe patients) were enrolled in a retrospective study. We proposed 3D V-Net to segment adrenal glands in onset CT images automatically, and periadrenal fat was obtained using inflation operation around the adrenal gland. Next, we built a clinical model (CM), three radiomics models (adrenal gland model [AM], periadrenal fat model [PM], and fusion of adrenal gland and periadrenal fat model [FM]), and radiomics nomogram (RN) after radiomics features extracted to predict disease progression in patients with COVID-19.
Results The auto-segmentation framework yielded a dice value of 0.79 in the training set. CM, AM, PM, FM, and RN obtained AUCs of 0.712, 0.692, 0.763, 0.791, and 0.806, respectively in the training set. FM and RN had better predictive efficacy than CM (P < 0.0001) in the training set. RN showed that there was no significant difference in the validation set (mean absolute error [MAE] = 0.04) and test set (MAE = 0.075) between predictive and actual results. Decision curve analysis showed that if the threshold probability was more than 0.3 in the validation set or between 0.4 and 0.8 in the test set, it could gain more net benefits using RN than FM and CM.
Conclusion Radiomics features extracted from the adrenal gland and periadrenal fat CT images may predict progression in patients with COVID-19.
Funding This study was funded by Science and Technology Foundation of Guizhou Province (QKHZC [2020]4Y002, QKHPTRC [2019]5803), the Guiyang Science and Technology Project (ZKXM [2020]4), Guizhou Science and Technology Department Key Lab. Project (QKF [2017]25), Beijing Medical and Health Foundation (YWJKJJHKYJJ-B20261CS) and the special fund for basic Research Operating Expenses of public welfare research institutes at the central level from Chinese Academy of Medical Sciences (2019PT320003).
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
2020, NO.01
Funding Statement
This study was supported Science and Technology Foundation of Guizhou Province (QKHZC[2020]4Y002,QKHPTRC[2019]5803), the Guiyang Science and Technology Project (ZKXM[2020]4), Guizhou Science and Technology Department Key Lab. Project (QKF[2017]25), Beijing Medical and Health Foundation (YWJKJJHKYJJ-B20261CS) and Special Fund for basic Research Operating Expenses of public welfare research institutes at the central level of Chinese Academy of Medical Sciences (2019PT320003).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This multicenter study was approved by the ethics committees of Guizhou Provincial People' s Hospital (2020, NO. 01).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# Mudan Zhang and Xuntao Yin contributed equally to this work.
Data Availability
The database used and/or analysed during the current study are available from the corresponding author on reasonable request.